IFNA1 and myeloid sarcoma: Overall, the general trends of decreasing healthcare costs and increasing productivity losses that were observed in this study are in line with previous COI studies in MS with a similar longitudinal design.18 19 No significant differences in healthcare costs were observed between the IFN and GA, while NAT had higher healthcare costs (p value<0.05).